RAPT Therapeutics — Investor Presentation (September 2021)
26 slides from RAPT Therapeutics's investor presentation, Sep 27, 2021
Slide 1: Transforming the Treatment of Cancer and Inflammation
Transforming the Treatment of Cancer and Inflammation Corporate Presentation September 2021 Exhibit 99.1
Slide 2: Legal Disclaimers
Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the "Company," "we," or "us") research and clinical development pl
Slide 3: Oral Drugs Targeting Critical Immune Drivers of Disease
DISCOVERY Oral Drugs Targeting Critical Immune Drivers of Disease RPT193 (Inflammation): Oral agent targets inflammatory Th2 cells PoC in Phase 1b achieved in AD: efficacy on all key exploratory endpoints with excellent safety and tolerability FLX475 (Oncology): Selectively targets immunosuppressive
Slide 4: Proprietary Drug Discovery and Development Engine
Proprietary Drug Discovery and Development Engine R Drug discovery Clinical development to POC Rapid Interrogating clinically-relevant big datasets to identify targets and biomarkers Driven by data to improve chances of clinical success Critical immune drivers of cancer and inflammation A Analytics
Slide 5: RPT193: CCR4 Antagonist for Inflammatory Diseases
RPT193: CCR4 Antagonist for Inflammatory Diseases
Slide 6: RPT193: Oral CCR4 Antagonist for Inflammatory Diseases
RPT193: Oral CCR4 Antagonist for Inflammatory Diseases RPT193 is a highly potent and selective once-daily oral CCR4 antagonist that targets inflammation more specifically than JAK inhibitors and acts upstream of the injectables Phase 1b trial demonstrated clear benefit in patients with moderate-to-s
Slide 7: RPT193 Targets Th2 Cells: Key Drivers of Inflammation
RPT193 Targets Th2 Cells: Key Drivers of Inflammation in Atopic Dermatitis, Asthma, and Other Diseases Epithelial Barrier Surface CCR4 Th2 IL-5 IL-4 IL-13 Inflammation Thickening Itch Signaling via CCR4 regulates Th2 cell migration into inflamed tissues and enhances cytokine secretion Cytokines Alle
Slide 8: Atopic Dermatitis and Asthma Represent Major Markets
Atopic Dermatitis and Asthma Represent Major Markets Atopic Dermatitis (AD) Common disease affecting ~19M adults and ~10M children in the US $24B projected market by 2029* Asthma Asthma affects ~15M adults and children in the US $21B projected market by 2029* High unmet need: a well-tolerated, safe
Slide 9: Phase 1b Trial Explored RPT193 Activity in Moderate-to-Severe Atopic Dermatitis
Enrolled 31 patients into a double-blind, randomized trial with 2:1 allocation of RPT193 to placebo Monotherapy study: steroid and immunosuppressant washout period; rescue steroids not permitted through Day 43 Trial was not powered for any specific endpoint Exploratory endpoints include: EASI, Pruri
Slide 10: Phase 1b Baseline Demographics
Phase 1b Baseline Demographics Placebo RPT193 N 10 21 Age, Mean (Range) 35.8 (22-64) 41.0 (19-63) Female, n (%) 4 (40.0%) 12 (57.1%) Baseline Characteristics EASI, Mean (Range) 21.07 (13.6-45.5) 18.49 (12-30) BSA, Mean (Range) 24.5 (10-61) 23.3 (11-55) vIGA 3, n (%) 8 (80.0%) 18 (85.7%) Peak NRS, Me
Slide 11: RPT193 Differentiated from Placebo for EASI and EASI-50 at Day 29
RPT193 Differentiated from Placebo for EASI and EASI-50 at Day 29 with Further Improvement at Day 43 % Improvement in EASI Proportion of EASI-50 19.3% 43.6% 32.9% 41.9% Follow-up Treatment Follow-up Treatment *p < 0.05 * *
Slide 12: RPT193 Differentiated from Placebo for vIGA Clear/Almost Clear
RPT193 Differentiated from Placebo for vIGA Clear/Almost Clear at Day 29 with Further Differentiation at Day 43 0.0% 0.0% 4.8% 14.3% Proportion of vIGA 0/1 (Clear/Almost Clear)
Slide 13: RPT193 Demonstrated Clinically Meaningful Improvement in Itch
RPT193 Demonstrated Clinically Meaningful Improvement in Itch Compared to Placebo at Day 29 Proportion of NRS-4* 22.2% 45.0% *At least a 4-point improvement among patients with a baseline pruritis NRS ≥4
Slide 14: Phase 1b Safety
Phase 1b Safety No SAEs reported All AEs reported were mild or moderate in intensity No clinically significant safety laboratory abnormalities observed Overall safety profile to date suggests a well-tolerated oral drug that should not require laboratory safety monitoring
Slide 15: RPT193 6-Week Efficacy Compared to Other Drugs at 12-16 Weeks
RPT193 6-Week Efficacy Compared to Other Drugs at 12-16 Weeks* RPT193 RPT193 400 mg Biologics Orals Dupilumab Ph3 (300 mg q2wk) Lebrikizumab Ph2 (250 mg q2wk) Tralokinumab Ph3 (300 mg q2wk) Abrocitinib Ph3 (200 mg) Baricitinib Ph3 (2 mg) Etrasimod Ph2 (2 mg) Upadicitinib Ph2,3 (15 mg) % EASI improve
Slide 16: Next Steps for the RPT193 Program
Next Steps for the RPT193 Program RPT193 Phase 2 Trials Phase 1b Atopic Dermatitis Phase 2b Atopic Dermatitis Phase 2a Asthma PoC Achieved Adults with moderate-to-severe AD 16-week dosing period Multiple dose levels of RPT193 vs. placebo Goal: Evaluate efficacy and safety at 16 weeks and determine o
Slide 17: RPT193 Program Summary
RPT193 Program Summary Data from the Phase 1b study in patients with atopic dermatitis demonstrated clear benefit on all key exploratory clinical endpoints including EASI and vIGA Continued deepening of responses through the 2-week follow-up period suggests higher levels of efficacy could be achieve
Slide 18: FLX475: CCR4 Antagonist for Oncology
FLX475: CCR4 Antagonist for Oncology
Slide 19: Treg Are Key Targets in the Tumor Microenvironment
Treg Are Key Targets in the Tumor Microenvironment (TME) Correlate with poor prognosis across most cancers Mechanism for immune evasion by viruses and tumors Barrier to checkpoint inhibitor efficacy Challenge: selective inhibition of Treg in the TME Depleting antibodies targeting CD25, CCR4, etc. do
Slide 20: FLX475: Oral CCR4 Antagonist in Phase 2
FLX475: Oral CCR4 Antagonist in Phase 2 Highly potent and selective CCR4 small molecule antagonist Selectively blocks tumor Treg while sparing normal tissues and beneficial cells Potential for superior safety and efficacy compared to depleting antibodies Issued U.S. composition of matter patent with
Slide 21: Identification and Characterization of Charged Tumors
Identification and Characterization of Charged Tumors “Charged” tumors: high levels of CCR4 ligands, Treg and CD8 T cells Potential for both monotherapy and combination activity Represent cancers with high unmet need and large markets Potential for tissue-agnostic accelerated approval in virally- as
Slide 22: Phase 2: Gated Simon 2-Stage Design
Phase 2: Gated Simon 2-Stage Design FLX475 Monotherapy FLX475 w/ Pembrolizumab Nasopharyngeal (EBV+) Non-Small Cell Lung (CPI Experienced) Hodgkin/Non-Hodgkin Lymphoma (EBV+) Head & Neck (CPI Naïve) Cervical (HPV+) (CPI Naïve) TN Breast (CPI Naïve) Head & Neck (CPI Naïve) Head & Neck (CPI Experience
Slide 23: Updated Stage Decisions (September 2021)
Updated Stage 2 Decisions (September 2021) Nasopharyngeal (EBV+) Monotherapy Nasopharyngeal (EBV+) Monotherapy Nasopharyngeal (EBV+) Combination Go to Stage 2 Stop Stage 1 Stage 2 Decision EBV+ Lymphoma Monotherapy EBV+ Lymphoma Mono and Combo Stage 1 Pending NSCLC (CPI Experienced) Combination Cerv
Slide 24: FLX475 Phase 2 Program Summary
FLX475 Phase 2 Program Summary FLX475, a highly selective tumor Treg inhibitor, appears to be an active agent in charged cancers Demonstrated clinical activity as monotherapy Demonstrated clinical activity in combination with pembrolizumab in checkpoint-naïve cancers beyond expected from checkpoint
Slide 25: Key Takeaways and Upcoming Milestones
Key Takeaways and Upcoming Milestones RPT193: safe oral agent designed for an array of inflammatory diseases – Positive Phase 1b data in AD FLX475: a highly selective tumor Treg inhibitor in multiple Phase 2 expansions as monotherapy and in combination with pembrolizumab Next Key Milestones Sept 202
Slide 26: Thank You
Thank You
RAPT Therapeutics — Investor Presentation (September 2021) on 6ix